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BH3 domain of BID induces potent and selective apoptosis of 
non-small cell lung cancer cells: mechanisms and implications for 
therapy
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Apoptosis resistance is a hallmark of cancer and contributes to chemo-
resistance particularly in non-small cell lung cancer (NSCLC). Mul-
tidomain protapoptotic proteins BAX and BAK are critically regulate 
apoptosis through mitochondrial outer membrane permeabilization 
(MOMP), however their regulation at the NSCLC mitochondrial sur-
face has not been explored. The death-inducing BH3 domain of the ca-
nonical BAX/BAK activator BID, when coupled to an N-octoarginine 
cell delivery moiety, triggered rapid mitochondrial depolarization (MD) 
in NSCLC but not bronchial epithelial cells (BECs). Carboxyﬂuoresce-
in conjugation of BH3BID conﬁrmed rapid uptake into both cell types. 
MD was completely prevented by mutation of BH3BID (L90®A). 
Isolated NSCLC but not BEC mitochondria released cytochrome C 
within 15 minutes of BH3BID followed by SMAC. BAK conformation 
change an N terminus exposure was only induced in NSCLC mito-
chondria. BH3BID induced MD in a sequence dependent manner in 
isolated NSCLC mitochondria with marked alteration in mitochondrial 
ultrastructure, and was inhibited by double siRNA knockdown of BAX 
and BAK, by exogenous cytochrome C, or by mitochondrial apoptosis 
channel blocker (±)-1-(3,6-Dibromocarbazol-9-yl)-3-piperazin-1-yl-
propan-2-ol, bis TFA. Artiﬁcally induced MOMP (by digitonin permea-
bilization), was sufﬁcient to induce MD, consistent with uncoupling 
of electron transport following subtotal mitochondrial cytochrome C 
release. Although NSCLC but not BEC mitochondria expressed several 
antiapoptotic BCL-2 family proteins (BCL-2, BCL-XL, MCL-1, A1) 
and endogenous activator BH3 proteins BID and BIM, their double 
knockdown by siRNA did not inhibit BH3BID induced MD in NSCLC 
mitochondria. Crosslinked NSCLC mitochondria conﬁrmed both 
monomeric and high molecular weight complexes of BAX and BAK. 
In conclusion, BH3BID selectively kills NSCLC cells by targeting 
mitochondrial BAX and BAK and does not require BH3 proteins for 
toxicity. This pharmacology may be therapeutically exploitable as a 
means of achieving targeted NSCLC apoptosis. 
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Coagulation/fibrinolysis activation in advanced non small cell lung 
cancer: tumor invasion or venothrombotic complication
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Haemostatic abnormalities are found in the most of patients with 
advanced cancer, including lung cancer. Because there is a growing 
number of observations concerning the potential of anticoagulant 
agents to prolong survival in tumor patients, a detailed characterization 
of haemostatic markers in lung cancer is needed. 
The aim of our study was to explore whether the activation of coagula-
tion/ﬁbrinolysis 
is more a marker of tumor stage or venothrombotic complications in 
patients with advanced non-small cell lung cancer (NSCLC).
In 92 patients mean aged 61 years ±8,21 with NSCLC stage IIIB/IV 
venous ultrasound (VUS)was performed before chemotherapy. We 
measured in our patients concentration of D-dimer, tissue factor (TF), 
tissue factor pathway inhibitor (TFPI), thrombin -activatable ﬁbrynoly-
sis inhibitor (TAFI), plasmiongen activator inhibitor type-1 and type-2 
(PAI-1 and PAI-2) and urokinase-type plasminogen activator receptor 
(uPAR). The measurements of these markers were performed in 24 
healthy controls as well.
None of our patients with NSCLC had signs of proximal venous leg 
thrombosis in VUS. The mean values of measured parameters are listed 
in table 1. D-dimer and TF levels were signiﬁcantly elevated in NSCLC 
pts whereas TAFI levels were normal though higer than in controls.





831 476 380 150 <500
TF pg/ml 394 249 211 137 <255
TFPI pg/ml 1160 232 798 235 148-834
TAFI ug/ml 9,2 4,47 7,32 3,04 4-15
PAI -1 ng/ml 105 35 63,3 37,5 2-47
PAI-2 ng/ml not  detectable     
uPAR 1,15 0,96   <0,1
Conclusion: Signiﬁcant activation of TF pathway and plasminogen 
cascade observed in patients with advanced NSCLC is probably related 
to adnanced tumor stage than to thrombotic complication. PAI-1 acts 
synergistic to u-PAR in promotion of cancer invasion, in contrast to 
PAI-2, which was undetectable in our patients.
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Crowding makes a lung cancer cell line grow slower
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Background: The hypothesis of this study was that modulation of 
space affects proliferation rate in cancer cells allowing it to adapt to 
changing environment.
Materials and Methods: A squamous cell carcinoma cell line, U-
1752, was tested. Subcultivating was performed twice a week, during 
three weeks preserving 1/3, 1/5, 1/7 and 1/10 respectively. The experi-
ment was performed in duplicates. 
Via plotting the cell number as if all cells had been preserved at each 
subcultivation a doubling time for each subcultivation group was 
obtained. The fraction of proliferating cells was studied immunohisto-
chemically with antibodies against Ki67.
Results: The results showed a doubling time of 52 hours in the 1/3 
subcultivation group. The doubling time was gradually shorted in each 
group and when 1/10 of the cells were spared the doubling time was 
only 30 hours.
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Expression of Ki67 was 11% when 1/3 of the cells were spared but 
augmented till 36% when only 10% were spared.
The viability ranged between 93-98% with the highest in the 1/10 sub-
cultivation group and the lowest in the 1/3 subcultivation group.
Conclusion: We could thus demonstrate a remarkable ability of this 
cell line to adapt to changing conditions. A decrease in doubling time 
up to 50 % due to reducing number of cells in each cell culture dish at 
subcultivation was seen. This accelerated proliferation seems to mainly 
have been accomplished by recruiting a higher fraction of cells in pro-
liferation reﬂected by the increased Ki67 expression. 
An accelerated proliferation might be of importance clinically, for 
example considering the effect of fractionated irradiation in a radiosen-
sitive cell population.
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Induction of apoptosis by rhein via reactive oxygen species 
production, GADD153 expression, and caspase-3 activation in 
human lung cancer A-549 cells
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Background: Although rhein had been shown to induce apoptosis in 
several cancer cell lines, the action mechanism of rhein induced cell 
cycle arrest and apoptosis at the molecular level is not well known. 
Method: In this study, we use ﬂow cytometry analysis of DNA content 
for cell cycle and apoptosis from A-549 cells treated with different 
concentrations of rhein; Poly (ADP ribose) monoclonal antibody assay 
for apoptosis in A-549 cells after treated with rhein; inhibition of rhein-
induced apoptosis by the caspase-3 inhibitor Ac-DEVD-CHO in A-549 
cells etc. We investigated the mechanisms of rhein on a human lung 
cancer A-549 cell that induce G0/G1 phase arrest and ROS and Ca2+ 
productions that play an important role for apoptosis which are char-
acterized by caspase activation and mitochondria dependent pathway. 
Rhein induced G0/G1 arrest through inhibition of cyclin D3, Cdk4, 
Cdk4, and Cyclin E. 
Result: The efﬁcacious induction of apoptosis was observed at 50 μM 
for 12 h and up to 72 h examinations which were examined by ﬂow 
cytometric method. Flow cytometric analysis demonstrated that rhein 
induced the loss of mitochondrial membrane potential (Δ m), cyto-
chrome c release from mitochondrion, promoted capases-9 activation 
then promoted the activation of caspase-3 and led to apoptosis. Rhein 
also increased the levels of Gadd153, p53, p21, Bax and cytochrome 
c but decreased the levels of Bcl-2. The Ca2+ chelator BAPTA was 
added to the cells before rhein was added to the cells, and it blocked the 
Ca2+ production and also inhibited rhein-induced apoptosis in A-549 
cells. 
Conclusions: Our data demonstrated that rhein induces apoptosis in 
A-549 cells via a Ca2+-dependent mitochondrial death pathway. 
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Focal adhesion paxillin induces nodular cell growth, invasion, and 
angiogenesis in lung cancer
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Lung cancer is characterized by abnormal cell growth, invasion, 
and angiogenesis. The actin cytoskeleton plays a major role in these 
processes. In lung cancer tissues, but not other tumors, we have found 
that paxillin can be overexpressed, ampliﬁed, or mutated. In vivo 
properties of mutant paxillin (A127T) and wild type paxillin-express-
ing cells in nude mice were determined utilizing H522 NSCLC cell 
line in a mouse xenograft model.H522 has no signiﬁcant expression 
of paxillin,therefore the properties of paxillin-transfected cells could 
be studied. Tumor growth in the A127T mutant paxillin markedly 
exceeded (P = 0.0019) that in the control vector or wild-type paxillin. 
H522 cells grew in nude mice as a solid mass without any invasion or 
angiogenesis, whereas both wild-type paxillin and the A127T paxillin 
mutant expressing H522 cells grew as nodular tumors. In addition to 
nodularity, A127T paxillin expressing H522 xenograft tumors were 
highly invasive into the adjacent muscle tissue. Upon gross examina-
tion, the A127T paxillin tumors had larger nodules as compared to the 
wild-type paxillin tumors. Tumor sections from mice in various groups 
were examined using antibodies speciﬁc for nuclear antigen Ki-67 (a 
marker for active cell division), CD31 (measuring microvessel density, 
MVD) and VEGF (vascular endothelial growth factor). There was 
enhanced cell proliferation, increased stroma, increased MVD and in-
creased VEGF expression in wild type paxillin H522 xenografts. In the 
A127T paxillin H522 xenografts, as compared to paxillin negative or 
wild-type paxillin positive cells, there was enhanced cell proliferation 
with decreased stroma formation, MVD, and VEGF. There was a strong 
correlation between paxillin expression and angiogenesis (p=0.01). In 
conclusion, results from this study establish an important role for paxil-
lin in lung cancer.
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Amplification of c-Met in a subset of lung cancer cells leads to 
activation of m-Tor pathway
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Non-small cell lung cancer (NSCLC) is a difﬁcult disease to treat. 
Even with the best therapies and the recent advent of novel molecularly 
targeted therapies, the overall survival for all NSCLC patients is only 
20% over a ﬁve year period. c-Met receptor tyrosine kinases (RTKs) 
have been shown to be important in a variety of malignancies. We 
have examined the expression and gene ampliﬁcation of c-Met recep-
tor in various NSCLC cell lines using standard immunoblotting and 
FISH analysis respectively. It was found that there was overexpression 
of c-Met in most of the NSCLC cell lines (~75%), including H441, 
SKLU-1, H1993, A549, H1838, H358 and SW1573 except H-522 and 
H661. This was also evident in the lung tumor tissue immunoblotting 
and parafﬁn embedded lung cancer tissue micro array. FISH analysis 
revealed ampliﬁcation of the c-Met region on chromosome 7p11.2 to 
copy number 15 in 22% (two out of nine) of NSCLC cell lines, and 
correlated with high expression. Constitutively activated c-Met was 
